Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 8/20 | 0.45 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8688537 | 0.94 | DRD3 (0.50) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8689595 | 0.89 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL9018943 | 0.87 | DRD3 (0.50) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL30705737 | 0.87 | DRD3 (0.50) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8691516 | 0.83 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL30705735 | 0.83 | DRD3 (0.46) | DRD3DRD2DRD4HTR1DHTR1B | |
| Cyclopropane Carboxylic Acid SCHEMBL19989732 | 0.81 | DRD3 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL8689579 | 0.78 | DRD3 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL30705739 | 0.78 | DRD3 (0.48) | DRD3DRD2DRD4HTR1DHTR1B | |
| SCHEMBL10447705 | 0.77 | DRD3 (0.60) | DRD3DRD2DRD4HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062395-A1 | USE OF 5-METHOXY-2-AMINOINDAN (\"MEAI\") IN METHODS FOR TREATING METABOLIC SYNDROME | Clearmind Medicine Inc. (IL) | 2024-03-28 | — | — | WO | disclosed |
| US-11528924-B2 | Alcoholic beverage substitutes | Clearmind Medicine, Inc. (CA) | 2022-12-20 | — | — | US | disclosed |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | CLEARMIND LABS CORP. (CA) | 2021-10-28 | — | — | US | disclosed |
| EP-3705469-A1 | BINGE BEHAVIOR REGULATORS | GOLAN, Ezekiel (CA) | 2020-09-09 | — | — | EP | disclosed |
| EP-3230255-B1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (CA) | 2020-03-18 | — | — | EP | disclosed |
| EP-3230256-B1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (CA) | 2019-11-13 | — | — | EP | disclosed |
| US-20170360067-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | CLEARMIND LABS CORP. (CA) | 2017-12-21 | — | — | US | disclosed |
| EP-3230255-A1 | BINGE BEHAVIOR REGULATORS | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| EP-3230256-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | Golan, Ezekiel (CA) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092546-A1 | BINGE BEHAVIOR REGULATORS | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092547-A1 | ALCOHOLIC BEVERAGE SUBSTITUTES | GOLAN EZEKIEL (IL) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330609-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | TAS2R14 337/4885DRD3 131/4885DRD2 62/4885 |
| US-11528924-B2 | Alcoholic beverage substitutes | ADH1A, ADH5, ADH1C | TAS2R14 288/4885DRD3 431/4885DRD2 456/4885 |
| US-20210330608-A1 | BINGE BEHAVIOR REGULATORS | GABRB3, GABRB2, GABRB1 | TAS2R14 337/4885DRD3 131/4885DRD2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.